These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 513481)

  • 41. Effects of saralasin on renal function of the rat.
    Hofbauer KG; Bauereiss K; Zschiedrich H; Gross F
    Prog Biochem Pharmacol; 1976; 12():63-83. PubMed ID: 1019171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal vein renin and saralasin testing in renovascular hypertension.
    MacCarthy EP; Stokes GS
    Am Heart J; 1978 Nov; 96(5):697-8. PubMed ID: 400749
    [No Abstract]   [Full Text] [Related]  

  • 43. [Renin-angiotensin and vasopressin in the pathogenesis of malignant hypertension].
    Möhring J
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():157-66. PubMed ID: 349924
    [No Abstract]   [Full Text] [Related]  

  • 44. Detection of renovascular hypertension: saralasin test versus renin determinations.
    Marks LS; Maxwell MH; Smith RB; Cahill PJ; Kaufman JJ
    J Urol; 1976 Oct; 116(4):406-9. PubMed ID: 1053323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intrarenal effects of the renin-angiotensin system.
    Ploth DW; Navar LG
    Fed Proc; 1979 Aug; 38(9):2280-5. PubMed ID: 456614
    [No Abstract]   [Full Text] [Related]  

  • 46. Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats.
    Thomson SC; Tucker BJ; Gabbai F; Blantz RC
    J Clin Invest; 1989 Mar; 83(3):960-9. PubMed ID: 2921329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute reversal by saralasin of multiple intrarenal effects of angiotensin II.
    Steiner RW; Blantz RC
    Am J Physiol; 1979 Nov; 237(5):F386-91. PubMed ID: 495754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin.
    Yared A; Kon V; Ichikawa I
    J Clin Invest; 1985 May; 75(5):1477-87. PubMed ID: 3998146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Action of the competitive angiotensin II antagonist saralasin during the initial phase of glycerol-induced acute renal failure of the rat.
    Greven J; Klein H
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Dec; 301(2):139-43. PubMed ID: 600326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of saralasin on normal blood pressure and on reno-vascular hypertension (author's transl)].
    Beckerhoff R; Vetter W; Furrer J; Nussberger J; Schmied U; Siegenthaler W
    Dtsch Med Wochenschr; 1976 Mar; 101(11):398-401. PubMed ID: 1253700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal vascular responses to infusions of 1-sarcosine-8-alanine-angiotensin II (saralasin) in man and dog [proceedings].
    Lewis PS; Wilcox CS
    J Physiol; 1978 Jul; 280():42P-43P. PubMed ID: 690897
    [No Abstract]   [Full Text] [Related]  

  • 53. [Arterial hypertension and maintenance hemodialysis: effects of specific inhibition of angiotensin II by saralasin acetate].
    Mimran A; Deschodt G; Shaldon S; Barjon P; Mion C
    Arch Mal Coeur Vaiss; 1978 Jul; 71 Spec No():19-24. PubMed ID: 101176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pheochromocytoma and vasodepressor response to saralasin.
    Zawada ET; Dornfeld L; Maxwell M; Marks L; Kaufman JJ
    Ann Intern Med; 1979 Sep; 91(3):494-5. PubMed ID: 475193
    [No Abstract]   [Full Text] [Related]  

  • 55. Dopamine and saralasin antagonism of renal vasoconstriction and oliguria caused by amphotericin B in dogs.
    Reiner NE; Thompson WL
    J Infect Dis; 1979 Oct; 140(4):564-75. PubMed ID: 512416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic hemodynamic and hormonal responses during angiotensin II blockade with saralasin.
    Roos JC; Geyskes GG; Boer P; Dorhout Mees EJ
    J Cardiovasc Pharmacol; 1981; 3(5):1106-15. PubMed ID: 6168855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathophysiological concepts of renovascular hypertension.
    Brunner HR; Gavras H
    Contrib Nephrol; 1976; 3():20-9. PubMed ID: 1026366
    [No Abstract]   [Full Text] [Related]  

  • 58. Neural contribution to renal hypertension following acute renal artery stenosis in conscious rats.
    Faber JE; Brody MJ
    Hypertension; 1983; 5(2 Pt 2):I155-64. PubMed ID: 6337957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Negative saralasin response in correctable renovascular hypertension.
    Trainin EB; Lala VR; Gomez-Leon G; AvRuskin TW
    J Pediatr; 1978 Sep; 93(3):460-2. PubMed ID: 690764
    [No Abstract]   [Full Text] [Related]  

  • 60. Outpatient experience with saralasin.
    Streeten DH; Anderson GH
    Kidney Int Suppl; 1979 Mar; (9):S44-52. PubMed ID: 289863
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.